All Publications
7 min read

Solstice Advanced Materials to Acquire Element Solutions for Approximately $14.5 Billion | ULF New York

M&A & Corporate Transactions

Solstice Advanced Materials to Acquire Element Solutions for Approximately $14.5 Billion

Solstice Advanced Materials has entered into a definitive agreement to acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion including net debt. The combination creates a scaled advanced materials and specialty chemicals platform spanning semiconductor manufacturing, advanced packaging, AI data center cooling, and thermal management.

U
ULF New York
7 min read

Transaction Overview

Solstice Advanced Materials has entered into a definitive agreement to acquire Element Solutions, Inc. in a cash-and-stock transaction valued at approximately $14.5 billion, including net debt. Under the terms of the agreement, Element Solutions shareholders will receive $10.00 in cash plus 0.500 shares of Solstice for each Element Solutions share, resulting in Element Solutions shareholders owning approximately 44% of the combined company following closing.

Solstice has secured a $4.7 billion bridge financing commitment from Goldman Sachs to fund the cash consideration. The transaction is expected to close in the first half of 2027, subject to customary closing conditions, required regulatory approvals, and shareholder approval from both Solstice and Element Solutions shareholders.

The combined company is expected to generate approximately $6.8 billion in pro forma net sales and an adjusted EBITDA margin of approximately 26% on a 2025 pro forma basis, as disclosed by Solstice.

Strategic Rationale: Platform Consolidation in Advanced Materials

Solstice's Post-Honeywell Context

Solstice Advanced Materials was spun off from Honeywell, inheriting a portfolio of specialty fluorine chemistry, refrigerants, and advanced materials technologies. The Element Solutions acquisition represents Solstice's first major post-separation platform consolidation — a pattern consistent with newly independent companies using their early years of independence to define their standalone strategic identity through transformative M&A.

Why Element Solutions

Element Solutions is a global specialty chemicals company with leading positions in electronics assembly materials, semiconductor fabrication chemicals, and industrial surface treatment. Its product portfolio is deeply embedded in the supply chains of semiconductor manufacturers, advanced packaging facilities, and electronics OEMs — making it a critical materials supplier to the AI infrastructure buildout.

The strategic logic of the combination is multi-dimensional:

Semiconductor and Advanced Packaging. Element Solutions supplies specialty chemicals used in wafer fabrication, advanced packaging (including chiplet interconnect and heterogeneous integration processes), and printed circuit board manufacturing. As AI accelerator chips require increasingly complex packaging architectures, the demand for high-performance specialty chemicals in this segment is structurally growing.

AI Data Center Cooling and Thermal Management. Both Solstice and Element Solutions have exposure to the data center thermal management market — a segment experiencing rapid growth as AI compute density increases power consumption per rack beyond the capacity of traditional air cooling. The combined portfolio positions the company to supply immersion cooling fluids, thermal interface materials, and related specialty chemicals to hyperscale data center operators.

Scale and Margin Expansion. The combination creates a platform with approximately $6.8 billion in pro forma net sales and a 26% adjusted EBITDA margin — a scale that enables greater R&D investment, broader customer relationships, and improved procurement leverage across shared raw material inputs.

Key Legal and Commercial Due Diligence Considerations

Cash-and-Stock Consideration Structure

The mixed cash-and-stock consideration structure introduces several legal and financial complexities:

Exchange Ratio and Price Protection. The 0.500 Solstice share component means Element Solutions shareholders bear Solstice stock price risk between signing and closing — a period expected to span approximately 12-18 months given the anticipated first-half 2027 closing timeline. The definitive agreement likely includes a collar mechanism or walk-away rights if Solstice's stock price moves materially, but the specific terms have not been publicly disclosed.

S-4 Registration Statement and Joint Proxy/Prospectus. Because Solstice is issuing new shares as part of the consideration, it must file an S-4 registration statement with the SEC covering the shares to be issued. The S-4 will include a joint proxy statement/prospectus that both companies will use to solicit shareholder approval. This process typically takes 4-6 months from filing to effectiveness, including SEC review and comment cycles.

Shareholder Approval. Both Solstice and Element Solutions shareholders must approve the transaction. Element Solutions shareholders are voting on the merger; Solstice shareholders are voting on the share issuance (which under NYSE rules requires approval when the issuance exceeds 20% of outstanding shares). Proxy advisory firms (ISS, Glass Lewis) will issue voting recommendations that can materially influence the outcome.

Bridge Financing and Permanent Financing

The $4.7 billion Goldman Sachs bridge commitment provides deal certainty for the cash component but is intended to be replaced with permanent financing (investment-grade bonds and/or term loans) before or at closing. Key considerations include:

  • Market flex provisions in the bridge commitment that allow Goldman to adjust pricing and terms if market conditions deteriorate
  • Ticking fees that increase the cost of the bridge over time, creating incentive to refinance quickly
  • Debt covenant package in the permanent financing that will constrain Solstice's post-closing financial flexibility
  • Credit rating impact — the leverage incurred to fund the $10.00 per share cash component will likely result in a ratings review by Moody's and S&P

HSR and Antitrust Review

At approximately $14.5 billion, the transaction will require HSR Act pre-merger notification and is likely to receive a Second Request given the size and the overlap between the parties' specialty chemicals portfolios. Key antitrust considerations include:

  • Product market definition in specialty chemicals is highly fact-specific — regulators will examine whether the parties compete in specific chemical formulations used in semiconductor manufacturing or electronics assembly
  • Customer concentration — if major semiconductor manufacturers (TSMC, Samsung, Intel) or electronics OEMs source competing products from both Solstice and Element Solutions, the DOJ or FTC may require divestitures in those product lines
  • International filings — given Element Solutions' global operations, parallel filings in the EU, China, South Korea, and other jurisdictions are likely, with China's SAMR review potentially on the critical path to closing

Patent Portfolio and Technology Due Diligence

Both companies hold substantial patent portfolios in specialty chemistry, materials science, and process technology. Due diligence should assess:

  • Freedom-to-operate in key product lines, particularly where the parties' R&D programs may have developed overlapping technologies
  • Cross-license agreements with semiconductor manufacturers or equipment suppliers that may contain change-of-control provisions
  • Trade secret protection protocols, particularly for proprietary formulations that may not be patented

Nuclear Fuel Cycle Regulatory Considerations

Solstice's fluorine chemistry heritage from Honeywell includes exposure to uranium hexafluoride (UF₆) and related nuclear fuel cycle applications. If Element Solutions has any exposure to nuclear-related specialty chemicals, the combination may trigger review under the Atomic Energy Act or require NRC notification — a niche but potentially timeline-critical regulatory workstream.

Post-Closing Integration

Integrating two specialty chemicals platforms of this scale involves significant operational complexity: manufacturing footprint rationalization, ERP system consolidation, sales force integration, and R&D portfolio prioritization. The 44% ownership stake retained by Element Solutions shareholders creates ongoing alignment incentives but also governance complexity in the combined board structure.

Implications for Turkish Companies and Investors

Semiconductor Supply Chain Exposure. Turkish companies with operations in electronics manufacturing, PCB assembly, or semiconductor packaging that source specialty chemicals from either Solstice or Element Solutions should monitor the integration process for potential supply disruptions, pricing changes, or product line rationalizations.

AI Infrastructure Materials. The combined company's focus on AI data center cooling and thermal management reflects the broader investment wave in AI infrastructure. Turkish companies or investors evaluating exposure to AI infrastructure supply chains — beyond compute hardware — should consider the specialty materials and chemicals layer as a structurally growing segment.

Large-Cap M&A Complexity. The Solstice / Element Solutions transaction illustrates the full complexity of large-cap public company M&A: dual shareholder votes, S-4 registration, multi-jurisdictional antitrust review, bridge financing, and an 18-month closing timeline. Turkish companies contemplating acquisitions of U.S. public companies — or being acquired by U.S. strategic buyers — should engage U.S. M&A counsel early to map the regulatory and process timeline accurately.

This alert is provided for informational purposes only and does not constitute legal advice. Transaction details are based on publicly available information as of the date of publication. For legal advice regarding M&A transactions, cross-border investments, or U.S. regulatory matters, please contact ULF New York.

Explore Topics

#M&A#advanced-materials#specialty-chemicals#semiconductor#AI#data-center#Solstice#Element-Solutions#Honeywell#antitrust#HSR#bridge-financing
U

Written by

ULF New York

ULF New York legal team — New York-based attorneys advising Turkish companies and investors on U.S. market entry, corporate law, real estate, and international trade.

Share this article

X
ULF New York Bülteni

ABD Hukuk Rehberlerini
Doğrudan Alın

E-posta adresiniz yalnızca ULF New York hukuki içerikleri için kullanılır. İstediğiniz zaman aboneliğinizi iptal edebilirsiniz.

Related analysis and guides

Further Reading

M&A & Corporate Transactions3 min read

Solstice / Element Solutions $14.5B Acquisition: Transaction Update — July 12, 2026

A follow-up update on the Solstice Advanced Materials / Element Solutions definitive agreement. The cash-and-stock transaction — $10.00 per share plus 0.500 Solstice shares, representing approximately 15% premium to Element Solutions' July 2 closing price — remains on track for a first-half 2027 close. A KAP scan as of July 12, 2026 shows no new Turkish public company disclosures in the merger, demerger, or tender offer categories.

Read article
M&A & Corporate Transactions6 min read

Solstice Advanced Materials to Acquire Element Solutions for Approximately $14.5 Billion

Solstice Advanced Materials has announced a definitive agreement to acquire Element Solutions Inc. for approximately $14.5 billion in enterprise value — a mixed cash-and-stock transaction offering Element shareholders $10.00 per share in cash plus 0.5 shares of Solstice. The deal creates a specialty chemicals and advanced materials platform with approximately $29 billion in combined enterprise value and $6.8 billion in annual sales, targeting AI infrastructure, semiconductor manufacturing, and data center thermal management markets.

Read article
M&A & Corporate Transactions9 min read

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for Approximately $10 Billion

Vertex Pharmaceuticals Inc. has announced a definitive agreement to acquire Crinetics Pharmaceuticals Inc. for approximately $10 billion in an all-cash transaction — $85 per share, representing a premium of approximately 102% to Crinetics' closing price. The deal brings Vertex a commercial-stage rare endocrine disease franchise anchored by FDA-approved Palsonify and a late-stage pipeline asset in congenital adrenal hyperplasia, with combined peak annual sales potential projected above $5 billion.

Read article
M&A & Corporate Transactions9 min read

Perfect Corp. to Go Private in Founder-Led Buyout at $2.00 Per Share

Perfect Corp. (NYSE: PERF), the AI-powered beauty and fashion technology company, has agreed to be taken private by ProjectNY — an acquisition vehicle controlled by founder and Chairman Alice H. Chang — at $2.00 per share in cash. The offer represents a premium of approximately 48.1% over the closing price on March 17, 2026, the last trading day before the initial non-binding proposal. The transaction is expected to close in Q4 2026, subject to shareholder approval and customary closing conditions.

Read article

Published

Monday, July 6, 2026

Back to Publications